Recombinant Human VSIG3 Fc Chimera Protein, CF

Recombinant Human VSIG3 Fc Chimera Protein (Catalog # 9229-VS) binds to Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera (7126-B7) with an ED50 of 0.0750 - 0.750 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VSIG3 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA.

  Recombinant Human VSIG3 Fc Chimera (Catalog # 9229-VS) binds to Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera (Catalog # 7126-B7) with an ED₅₀ of 0.0750 - 0.750 μg/mL.

• Source: Mouse myeloma cell line, NS0-derived human VSIG3 protein
  

  Human VSIG3 (Leu23-Gly245) Accession # BAC07546	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: BAC07546
• N-terminal Sequence: Leu23
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 50 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 56-69 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VSIG3 Fc Chimera Protein, CF

• Brain and testis-specific immunoglobulin superfamily protein
• BTIGSF
• BT-IgSF
• cancer/testis antigen 119
• CT119
• CXADR like 1
• CXADRL1
• IGSF11
• Igsf13
• immunoglobulin superfamily member 11
• immunoglobulin superfamily, member 11
• MGC35227
• V-set and immunoglobulin domain containing 3
• V-set and immunoglobulin domain-containing protein 3
• VSIG3
• VSIG3brain and testis-specific immunoglobin superfamily protein

Background

VSIG3, also known as IGSF11, BT-IgSF, and CLMP, is an approximately 50 kDa transmembrane adhesion protein (1). Mature human VSIG3 consists of a 219 amino acid (aa) extracellular domain (ECD) that contains two tandem Ig-like domains, a 21 aa transmembrane segment, and a 169 aa cytoplasmic domain (2). Within the ECD, human VSIG3 shares 95% aa sequence identity with mouse and rat VSIG3. Alternative splicing generates additional isoforms with a substituted signal peptide that may also have a deletion in the second Ig-like domain (3). VSIG3 is expressed on epithelial and endothelial cells, neurons and glial cells, and platelets (2-4). It localizes to epithelial tight junctions and mediates homophilic in trans cell adhesion (3-5). VSIG3 also localizes to neuronal postsynaptic densisties where it recruits the GluA1 and GluA2 subunits of AMPA receptors and supports excitatory synaptic transmission (6). The short isoform can be up-regulated in gastric cancer (7). In zebrafish, VSIG3 is expressed in melanophores and their precursors and plays a role in the development and patterning of pigment cells (8).

1. Schreiber, J. et al. (2014) Adv. Neurobiol. 8:21.
2. Suzu, S. et al. (2002) Biochem. Biophys. Res. Commun. 296:1215.
3. Katoh, M. and M. Katoh (2003) Int. J. Oncol. 23:525.
4. Raschperger, E. et al. (2004) J. Biol. Chem. 279:796.
5. Harada, H. et al. (2005) J. Cell. Physiol. 204:919.
6. Jang, S. et al. (2016) Nat. Neurosci. 19:84.
7. Watanabe, T. et al. (2005) Cancer Sci. 96:498.
8. Eom, D.S. et al. (2012) PLoS Genet. 8:e1002899.

Publications for VSIG3/IGSF11 (9229-VS)(2)

Publications using 9229-VS

• N Mehta, S Maddineni, II Mathews, R Andres Par, PS Huang, JR Cochran Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation Cell Rep, 2019-09-03;28(10):2509-2516.e5. 2019-09-03 [PMID: 31484064] (ELISA Capture, Human)
• Wang J, Wu G, Manick B, Hernandez V, Renelt M, Erickson C, Guan J, Singh R, Rollins S, Solorz A, Bi M, Li J, Grabowski D, Dirkx J, Tracy C, Stuart T, Ellinghuysen C, Desmond D, Foster C, Kalabokis V VSIG-3 as a ligand of VISTA inhibits human T-cell function. Immunology, 2018-10-10;156(1):74-85. 2018-10-10 [PMID: 30220083] (Bioassay, Human)

Bioinformatics

• Uniprot:
  • BAC07546()